Published in J Urol on December 01, 1990
Risk factors for emotional and relationship problems in Peyronie's disease. J Sex Med (2008) 1.14
Peyronie's Disease: A Review. Rev Urol (2003) 0.89
Current and emerging treatment options for Peyronie's disease. Res Rep Urol (2013) 0.86
Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease. Urol Ann (2015) 0.82
Peyronie's reconstruction for maximum length and girth gain: geometrical principles. Adv Urol (2008) 0.81
PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT. Curr Sex Health Rep (2015) 0.81
Review of the surgical approaches for Peyronie's disease: corporeal plication and plaque incision with grafting. Adv Urol (2008) 0.81
Urologists' Perceptions and Practice Patterns in Peyronie's Disease: A Korean Nationwide Survey Including Patient Satisfaction. Korean J Urol (2014) 0.80
A malignant differential diagnosis for Peyronie's disease. BMJ Case Rep (2014) 0.79
The pathophysiology of Peyronie's disease. Arab J Urol (2013) 0.79
Penile corporoplasty with Yachia's technique for Peyronie's disease: Single center experience with 117 patients. Urol Ann (2013) 0.79
Peyronie's Disease: Nonsurgical Therapy Options. Rev Urol (2011) 0.78
Psychological aspects of Peyronie's disease. Transl Androl Urol (2016) 0.77
Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects. Ther Adv Urol (2014) 0.77
Imaging modalities and clinical assesment in men affected with Peyronie's disease. Pol J Radiol (2011) 0.77
Couples-based interventions following prostate cancer treatment: a narrative review. Transl Androl Urol (2015) 0.76
Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases. Int J Androl (2011) 0.76
Psychosexual Symptoms and Treatment of Peyronie's Disease Within a Collaborative Care Model. Sex Med (2014) 0.76
US Imaging in Peyronie's Disease. J Clin Imaging Sci (2012) 0.75
Nonsurgical treatment options in Peyronie's Disease: 2016 update. Turk J Urol (2016) 0.75
Use of autologous grafts in the treatment of acquired penile curvature: An experience of 33 cases. Urol Ann (2016) 0.75
--- ---Recent advances in managing Peyronie's disease. F1000Res (2016) 0.75
A critical analysis of the surgical outcomes for the treatment of Peyronie's disease. Arab J Urol (2013) 0.75
The direction and severity of penile curvature does not have an impact on concomitant vasculogenic erectile dysfunction in patients with Peyronie's disease. Int J Impot Res (2014) 0.75
Structured Self-Rated Response to Iontophoresis with Verapamil and Dexamethasone in Peyronie's Disease. Adv Urol (2014) 0.75
Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie's disease: a retrospective analysis of 309 cases. Res Rep Urol (2016) 0.75
Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction. Transl Androl Urol (2017) 0.75
Tunical plication in the management of penile curvature due La Peyronie's disease. Our experience on 47 cases. BMC Surg (2012) 0.75
The role of Nesbit's procedure in surgical reconstruction of penile deviation. GMS Interdiscip Plast Reconstr Surg DGPW (2012) 0.75
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
BioJava: an open-source framework for bioinformatics. Bioinformatics (2008) 6.17
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol (2001) 4.22
Anti-lymphocytic antibody--a review. Clin Exp Immunol (1967) 2.75
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol (1996) 2.25
Human monoclonal antibody production. Current status and future prospects. J Immunol Methods (1987) 2.21
Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol (2001) 2.20
Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol (1997) 2.14
Laboratory staff qualifications and accuracy of proficiency test results. A national study. Arch Pathol Lab Med (1992) 2.07
Differences between patients' and physicians' evaluations of outcome after total hip arthroplasty. J Bone Joint Surg Am (1996) 1.89
Effect of antilymphocytic antibody and antibody fragments on human lymphocytes in vitro. Nature (1967) 1.89
Psychotic men remanded in custody to Brixton Prison. Br J Psychiatry (1994) 1.77
Interferon activation of "pre-spontaneous killer" (pre-SK) cells and alteration in kinetics of lysis of both "pre-SK" and active SK cells. J Immunol (1980) 1.75
Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br Med J (Clin Res Ed) (1983) 1.72
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res (2001) 1.61
A genomewide suppressor and enhancer analysis of cdc13-1 reveals varied cellular processes influencing telomere capping in Saccharomyces cerevisiae. Genetics (2008) 1.58
Some factors influencing the ability of anti-lymphocytic antibody to suppress humoral antibody formation. Clin Exp Immunol (1967) 1.52
Diagnosis of glenoid labral tears. A comparison between magnetic resonance imaging and clinical examinations. Am J Sports Med (1996) 1.52
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
Intraoperative frozen section monitoring of nerve sparing radical retropubic prostatectomy. J Urol (1999) 1.49
The preparation and properties of anti-lymphocytic sera. Prog Surg (1969) 1.48
Making do without randomised trials. J Bone Joint Surg Br (1994) 1.46
[Surgical treatment of the single non traumatic perforation of small bowel: excision-suture or resection-anastomosis]. Ann Chir (2005) 1.45
Arthroplasty of the first metatarsophalangeal joint with a double-stem silicone implant. Results in patients who have degenerative joint disease failure of previous operations, or rheumatoid arthritis. J Bone Joint Surg Am (1992) 1.45
Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol (2000) 1.43
Structure-property correlations in a combinatorial library of degradable biomaterials. J Biomed Mater Res (1998) 1.42
The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys (1997) 1.42
Continuous thoracic epidural analgesia versus combined spinal/thoracic epidural analgesia on pain, pulmonary function and the metabolic response following colonic resection. Acta Anaesthesiol Scand (1996) 1.42
Effect of antilymphocytic antibody and antibody fragments on skin-homograft survival and the blood-lymphocyte count in rats. Lancet (1967) 1.41
Effect of anti-rat lymphocyte antibody on humoral antibody formation. Nature (1967) 1.40
Survivorship analysis in the evaluation of joint replacement. J Arthroplasty (1986) 1.38
Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38
Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol (1999) 1.36
Notching of the femoral neck during resurfacing arthroplasty of the hip: a vascular study. J Bone Joint Surg Br (2006) 1.36
Deep sepsis following total knee arthroplasty. Ten-year experience at the University of California at Los Angeles Medical Center. J Bone Joint Surg Am (1986) 1.35
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1996) 1.32
The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol (1994) 1.29
Characterization of antilymphocytic antibody. Nature (1967) 1.27
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol (1998) 1.27
Characterization of symptomatic and asymptomatic carotid plaques using high-resolution real-time ultrasonography. Br J Surg (1993) 1.26
The distribution and possible significance of cells identified in human lymphoid tissue by the monoclonal antibody HNK-1. Clin Exp Immunol (1983) 1.25
Multiple organ damage caused by a new toxin azaspiracid, isolated from mussels produced in Ireland. Toxicon (2000) 1.23
Total femoral endoprosthetic reconstruction. Clin Orthop Relat Res (1995) 1.23
THARIES resurfacing arthroplasty. Evolution and long-term results. Clin Orthop Relat Res (1986) 1.22
New allele at cholinesterase locus 1. J Med Genet (1976) 1.20
Normal and pathological serum levels of alpha2-macroglobulins in men and mice. J Clin Pathol (1975) 1.18
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am (1997) 1.18
Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol (1994) 1.18
Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol (2000) 1.16
Prolongation of canine renal allograft survival with antilymphocytic serum. Transplantation (1968) 1.16
The effect of anti-lymphocytic antibody on the humoral immune response in different strains of mice. I. The response to bovine serum albumin. Immunology (1972) 1.15
Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol (1995) 1.14
Flexible eating and flexible insulin dosing in patients with diabetes: Results of an intensive self-management course. Diabetes Res Clin Pract (2008) 1.13
Quantitative studies with antilymphocytic antibody. Nature (1967) 1.13
The accuracy of assessing total hip arthroplasty outcomes: a prospective correlation study of walking ability and 2 validated measurement devices. J Arthroplasty (2000) 1.12
The antecedents of violence and aggression within psychiatric in-patient settings. Acta Psychiatr Scand (2012) 1.10
Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosus). Clin Exp Immunol (1967) 1.10
Binding of C-reactive protein to human lymphocytes. II. Interaction with a subset of cells bearing the Fc receptor. J Immunol (1981) 1.08
Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol (1993) 1.08
Preliminary observations on the effect of heterologous anti-lymphocytic globulin on autologous immune complex nephritis in rats. Clin Exp Immunol (1969) 1.06
Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis (2000) 1.06
Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology (2000) 1.06
Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy (2008) 1.05
Binding of C-reactive protein to human lymphocytes. I. Requirement for a binding specificity. J Immunol (1981) 1.05
Distribution of fatty and fibrous plaques in young human coronary arteries. Atherosclerosis (1982) 1.05
Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol (2000) 1.05
A membrane-covered photobacterium probe for oxygen measurements in the nanomolar range. Anal Biochem (1981) 1.04
Prediction of amputation wound healing with skin perfusion pressure. J Vasc Surg (1995) 1.02
Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol (2000) 1.02
Extracellular organelles (prostasomes) are immunosuppressive components of human semen. Clin Exp Immunol (1991) 1.02
Magnetic resonance imaging as a tool for evaluation of traumatic knee injuries. Anatomical and pathoanatomical correlations. Am J Sports Med (1986) 1.02
Synovial cells. A study of the morphology and an examination of protein synthesis of synovial cells. Ann Rheum Dis (1966) 1.02
Association of alpha-macroglobulins with lymphoid cells. Nat New Biol (1973) 1.01
Diazepam and lorazepam for intravenous surgical premedication. J Clin Pharmacol (1978) 1.01
In vitro studies on the heterogeneity of equine antibodies to human lymphoid tissue. Immunochemistry (1969) 1.00
Effect of Corynebacterium parvum on the class and subclass of antibody produced in the response of different strains of mice to sheep erythrocytes. Immunology (1975) 1.00
Comparison of immune derangements in patients with different malignancies. Cancer (1980) 1.00
The effect of anti-lymphocytic IgG on estab- lished autoallergic thyroiditis in rats. Clin Exp Immunol (1969) 0.99
Community empowerment in the control of lymphatic filariasis in Misima, Milne Bay Province using diethylcarbamazine in combination with albendazole. P N G Med J (2002) 0.99
Dppa3 is a marker of pluripotency and has a human homologue that is expressed in germ cell tumours. Cytogenet Genome Res (2003) 0.99
Outcome after total hip arthroplasty. Comparison of a traditional disease-specific and a quality-of-life measurement of outcome. J Arthroplasty (1997) 0.98
Studies on the Fc receptor bearing cells in a transplanted methylcholanthrene induced mouse fibrosarcoma. Br J Cancer (1976) 0.98
Preliminary studies on the synthesis of alpha2-macroglobulin by human lymphocytes in vitro. Clin Exp Immunol (1974) 0.98
Duration of symptoms and outcome of hemiresurfacing for hip osteonecrosis. Clin Orthop Relat Res (2001) 0.97
Association of host immunoglobulins with solid tumours in vivo. Br J Cancer (1979) 0.97
The effect of antilymphocytic antibody on the humoral immune response in different strains of mice. 3. The response to type 3 pneumococcus polysaccharide. Immunology (1973) 0.97
Lymphocyte sub-populations in the male genital tract. Br J Urol (1985) 0.97
Validation evidence for three coping measures. J Pers Assess (1995) 0.96
The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII. Thromb Haemost (1986) 0.96
A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem (2006) 0.96
Prolonged seated immobility at work is a common risk factor for venous thromboembolism leading to hospital admission. Intern Med J (2008) 0.95